$JAZZ news
The latest JAZZ stock news: headlines, filings, AI summaries and sentiment for $JAZZ, updated around the clock.
- Nuvation Bio Reports Third Quarter Revenue of $45 Million, Exceeding Estimates
- Jazz Pharmaceuticals Shares Rise Following Upward Revenue Guidance Revision
- Jazz Pharmaceuticals Reports Q3 2026 Results with Revenue Growth and Raised Guidance
- Jazz Pharmaceuticals Reports Record Q3 Revenue and Provides 2026 Guidance
- Jazz Pharmaceuticals Reports Q3 Revenue Beat Amid Significant Non-GAAP EPS Miss
- Jazz Pharmaceuticals plc - 10-Q Filing
- Jazz Pharmaceuticals plc - 8-K Filing
- Jazz Pharmaceuticals Scheduled to Report Q3 2026 Earnings
- Jazz Pharmaceuticals Reports $755 Million IPR&D Charge Following Actio Biosciences Acquisition
- Jazz Pharmaceuticals plc - 8-K Filing
- Jazz Pharmaceuticals plc - 8-K Filing
- Jazz Pharmaceuticals plc - 8-K Filing
- Jazz Pharmaceuticals Acquires Actio Biosciences for $820M to Expand Epilepsy Portfolio
- Jazz Pharmaceuticals Acquires Actio Biosciences for Potential Epilepsy Treatment
- CareTrust REIT Closes $400M Skilled Nursing Portfolio Deal, Expanding Record Year of Investments
- Westlake Chemicals Posts Profitable Q2 After Two Consecutive Losses
- Jazz Pharmaceuticals plc - 8-K Filing
- Jazz Pharmaceuticals plc - 8-K Filing
- Zymeworks Shares Rise Ahead of FDA Decision on Zanidatamab
- Jazz Pharmaceuticals plc - 8-K Filing
- Jazz Pharmaceuticals plc - 8-K Filing
- Jazz Pharmaceuticals and AbCellera Collaborate on Antibody Programs for Solid Tumors
- UBS Upgrades Jazz Pharmaceuticals with Significant Price Target Increase
- UBS Upgrades Jazz Pharmaceuticals with Significant Price Target Increase
- Morgan Stanley Raises Price Target on Jazz Pharmaceuticals to $245
- Zymeworks Q1 2026 Earnings Report Highlights Regulatory Catalysts and Financial Performance
- Jazz Pharmaceuticals Reports Q1 2026 Earnings with Strong Revenue Growth